•   
  •   
  •   

Health & Fit Covid-19: after "promising" trials, Sanofi offers 300,000 doses of antimalarials to treat patients

10:40  18 march  2020
10:40  18 march  2020 Source:   leparisien.fr

New discovery may lead to 'one-size-fits-all' cancer treatment one day, researchers say

  New discovery may lead to 'one-size-fits-all' cancer treatment one day, researchers say A team of researchers discovered a new type of immune cell that they say could one day be used as a "one-size-fits-all" therapy for most cancers.A team of researchers in the United Kingdom discovered a new type of immune cell that they say could one day be used as a "one-size-fits-all" therapy for most cancers.

Clinical trials on 24 coronavirus patients were " promising " and would be extended to more patients . 6 days after the start of taking Plaquenil, the virus had Sanofi said it could offer enough doses of Plaquenil - a drug containing the molecule hydroxychloroquine - to treat up to 300 , 000 people.

French pharmaceutical giant # Sanofi said it was ready to offer France millions of doses of anti-malaria treatment called Plaquenil, that early PagesMediaBooks and magazinesNewspaperDaily News EgyptVideosSanofi offers anti-malaria medicine to COVID - 19 patients , after promising trials .

The results of tests carried out on patients with coronavirus with this treatment are considered encouraging.

Le Parisien © AFP / Gérard Julien Le Parisien

As echoing the statements of French government spokeswoman Sibeth Ndiaye, who said on Tuesday that clinical trials were "promising" and would be extended to more patients, the French laboratory Sanofi has said it is ready to offer the French authorities millions of doses of the antimalarial Plaquenil. This drug could potentially treat 300,000 patients with Covid-19.

In view of a study with encouraging results conducted on this drug, "Sanofi is committed to making its treatment available to France and to offering several million doses that could treat 300,000 patients," said Tuesday. a spokesperson for the laboratory, while specifying that the group was ready to work with French health authorities "to confirm these results".

Coronavirus: Berlin uses Ebola medication for infected

 Coronavirus: Berlin uses Ebola medication for infected © provided by WUNDERWEIB Coronavirus: Berlin uses Ebola medication for infected There is still no vaccine against the new Sars-CoV-2 coronavirus. The Ebola drug Remdesivir could help with healing - and is now used in clinics in Berlin. As long as there is no vaccine against COVID-19, the virus will be easy. Researchers worldwide are testing various drugs that can help, but so far there are none that are specifically approved for Sars CoV-2 infection.

Both drugs are approved to treat malaria, lupus and rheumatoid arthritis, but must still be assessed in clinical trials before being declared a safe and effective COVID - 19 treatment . "We understand and recognize the urgency with which we are all seeking prevention and treatment options for COVID - 19 .

Patients received a single dose of 400 mg tocilizumab via intravenous infusion. In general, the patients improved with lower oxygen requirements, lymphocyte counts returned to normal, and 19 ARDS/lung injury. Dry powder inhaled formulation with potential to treat ARDS caused by COVID - 19 .

Three-quarters of people treated cured

Plaquenil, a molecule of hydroxychloroquine, also used for decades in autoimmune diseases like lupus or rheumatoid arthritis, could indeed have an effect on the disappearance of the virus, said Monday Professor Didier Raoult, director of the Institut Hospitalo-Universitaire de Marseille.

READ ALSO> Coronavirus: is chloroquine really a miracle cure?

According to this study carried out by Professor Raoult on 24 patients suffering from the coronavirus, six days after starting to take Plaquenil, the virus had disappeared in three quarters of the people treated.

These new clinical trials "will be carried out with a team independent of Professor (Didier) Raoult", specified Sibeth Ndiaye after a Council of Ministers, stressing that at this stage "we have no evidence scientific "that this treatment works. Several experts call for caution in the absence of further studies and because of the side effects which can be serious, especially in the event of an overdose.

Coronavirus: Sanofi and Regeneron test a treatment of rheumatoid arthritis in the USA

 Coronavirus: Sanofi and Regeneron test a treatment of rheumatoid arthritis in the USA SANTE-CORONAVIRUS-SANOFI: Coronavirus: Sanofi and Regeneron test a treatment of rheumatoid arthritis in the USA © Reuters / Christian Hartmann CORONAVIRUS: SANOFI AND REGENON TREATMENT OF RHUMATOID POLYARTHRITIS IN THE USA PARIS (Reuters) - Sanofi and its partner Regeneron have launched a clinical trial on their treatment of rheumatoid arthritis Kevzara in the treatment of hospitalized patients suffering from severe forms of new infection coronavirus, the two groups announced on Monday in a sta

on COVID - 19 treatment (14), 100% of patients treated with. Clinical trials . have demonstrated promising data on mortality improvement. in sepsis, but more extensive studies are and safety of thalidomide combined with low- dose hormones in the. treatment of severe Covid - 19 . Conclusions: In hospitalized adult patients with severe Covid - 19 , no benefit was observed with lopinavir-ritonavir

Australian researchers claim two existing drugs could 'cure' COVID - 19 after patients they tested Researchers now believe it may hold the key to treating COVID - 19 , the latest strain of coronavirus. Requests have been submitted in China to start a clinical trial of the drug to accurately determine its

"I have taken note of the results and have given the authorization so that a larger trial by other teams can be undertaken as soon as possible on a larger number of patients", de his side indicated during a telephone press conference the Minister of Health Olivier Véran.

Donations of hydroalcoholic gel

The latter expressed the hope that these new tests would "consolidate the interesting results" obtained by Professor Raoult. But "it is absolutely fundamental to base any decision of public health policy on validated scientific data, and the validation processes, one cannot negotiate with", he underlined about these tests.

Business initiatives are multiplying in the face of the pandemic. Last Friday, Sanofi, which is working on a vaccine against the new coronavirus, had already announced the creation of a seed fund to support the research effort of the teams of the Assistance Publique Hôpitaux de Paris (AP-HP) in their fight against the coronavirus.

Sunday, the luxury group LVMH also said it would act by announcing that its fragrance branch was going to manufacture hydroalcoholic gels made available free of charge to French health authorities.

Dispensed: A week of drug developments, the plan to restart hospitals, and some non-coronavirus news .
Welcome to Dispensed, BI's weekly healthcare newsletter. This week, the TLDR on remdesivir, a promising experimental coronavirus treatment.Welcome to Dispensed, Business Insider's weekly healthcare newsletter, in which we're contemplating how it could possibly already be May. I looked at my calendar this morning and calculated that I've been doing this work-from-home/social distancing thing for 51 days here in Brooklyn.

—   Share news in the SOC. Networks
usr: 0
This is interesting!